STOCKHOLM, Sweden, Sept. 13, 2005 (PRIMEZONE) -- A resolution was passed at Vitrolife's Extraordinary General Meeting on August 24, 2005 concerning warrants programs for Vitrolife employees and for the members of the Board of Vitrolife AB (publ).
The program directed at the employees was over-subscribed by approx. 30 percent. The warrants were thus allocated in proportion to the number subscribed for. The warrants program for the members of the Board of Vitrolife AB (publ) was fully subscribed.
"It is gratifying to see that our personnel feel such great confidence in and such commitment to the company," says Magnus Nilsson, Vitrolife's CEO. "After some tough years there is great self-confidence concerning both what we have achieved so far and our future opportunities."
The warrants program for the employees comprised a total of 490,000 separable warrants to subscribe for new shares, where each warrant gives the right to subscribe for one new share (each with a nominal value of SEK 1.0) in the company. Subscription for shares in accordance with the conditions for the warrants may take place during the period as from September 3, 2007 up until September 3, 2008. The subscription price amounts to SEK 30.90.
The warrants program for the members of the Board of Vitrolife AB (publ), excluding the Chairman of the Board and the proposer Skanditek's CEO Patrik Tigerschiold, comprised a total of 60,000 warrants. The conditions were otherwise the same as for the warrants program for the employees.
The full conditions for the program are available on the company's home page, www.vitrolife.com.
September 13, 2005 Kungsbacka, Sweden
Magnus Nilsson CEO
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has over 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
Vitrolife AB (publ), Faktorvagen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=129843&fn=wkr0001.pdf